The pharmaceutical sector continues to be an excellent arena for long-term investors seeking robust growth and stable returns. Today, we will take a detailed look at the recent financial indicators and investment recommendations for 'Venus Remedies,' a key player in the pharmaceutical manufacturing industry.
A Detailed Analysis of the Company's Recent Financial Indicators
If you are considering adding this company's shares to your investment portfolio, here are the key details you need to know, based on market data as of July 14, 2026.
- Key Overview: Stock Details & Investment Decision
- Current Share Price: ₹1,895.60 (as of 14.07.2026)
- Market Capitalization: ₹2,298 Crore
- Analyst Recommendation: BUY
- Investment Horizon: 5 Years
- Target Price: ₹3,380.26
- Key Highlight: Analysts project significant growth potential of nearly 78% from the current market price, with a target price of ₹3,380.26 over a five-year period.
Key Valuation and Financial Ratios
Understanding key valuation metrics is essential to determine whether the share price is reasonable relative to the company's earnings.
P/E Ratio (Price-to-Earnings Ratio): 22.40 — This indicates a reasonable valuation for a growing pharmaceutical company.
EV/EBITDA: 15.60x — This reflects how the market values the entire business relative to its operating profit. Free Cash Flow (FCF): ₹118 crore — This indicates a healthy cash position, enabling the company to reinvest in Research & Development (R&D) or repay debt.
Estimated EPS (Earnings Per Share) for 2030: ₹107.65 — A forward-looking projection indicating strong earnings per share by the end of the decade.
Factors to Consider
Market presence across 96 countries
Expansion of the distributor network (increased from 4,000 to 10,000)
Diverse product portfolio
Market authorizations for over 1,040 products
Robust financial position. Risks
Continuity of raw material supply
Over 70% of raw materials are imported from China
Strict global quality control standards
Profitability impacted by domestic price controls and global trade competition
Difficulty in sourcing skilled personnel and experts
Stringent environmental regulations posing challenges to success.
Valuation Outlook
Undervalued in the market
The market has yet to fully recognize the company's capabilities and potential
Note: Stock market investments are subject to market risks.
Please read all related documents carefully before investing. SEBI registration and NISM certification do not guarantee a research analyst's performance or investor returns.

Comments
Post a Comment
Like this 22k jewelers blog?